ATP-dependent intracellular enzyme

ATP-dependent intracellular enzyme refers to a diverse group of proteins that require the hydrolysis of adenosine triphosphate (ATP) to perform essential cellular functions, such as signal transduction, molecular transport, and protein folding (NIH, 2007). In clinical pharmacology, this broad category is recognized as the collective target for first-generation, non-nitrogen-containing bisphosphonates, including clodronate and etidronate (MDPI, 2021). These drugs act as prodrugs that are metabolically converted by aminoacyl-tRNA synthetases into non-hydrolyzable ATP analogs, such as adenosine 5'-(beta,gamma-dichloromethylene)triphosphate (AppCp) (ACS, 2022). These metabolites accumulate to high concentrations within bone-resorbing osteoclasts and competitively inhibit multiple ATP-dependent enzymes, thereby disrupting cellular metabolism and triggering programmed cell death (NIH, 2000). By inducing osteoclast apoptosis, these drugs effectively inhibit bone resorption and are used to treat metabolic bone disorders like osteoporosis and Paget's disease (NIH, 2007). However, because the target is a broad class of enzymes rather than a specific protein, the pharmacological effect is characterized by multi-enzyme inhibition within the targeted cell type (MDPI, 2021). This lack of specificity is a hallmark of early bisphosphonate therapy, distinguishing it from the more targeted inhibition of farnesyl pyrophosphate synthase by later-generation nitrogenous bisphosphonates (ACS, 2022). Understanding the role of these enzymes is crucial for managing bone density and preventing skeletal-related events in cancer patients (NIH, 2007).

Other names

ATP-dependent enzymesATP-utilizing enzymesIntracellular ATP-dependent enzymes

Metabolic incorporation into non-hydrolyzable ATP analogs (AppCp) that competitively inhibit various ATP-dependent enzymes, leading to the disruption of cellular energy metabolism and induction of apoptosis (NIH, 2007; MDPI, 2021).